Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP1 | O94782 | 10/20 | 0.44 |
| ▸ | WDR48 | Q8TAF3 | 9/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 7/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.36 |
| ▸ | HDAC5 | Q9UQL6 | 7/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31625263 | 0.89 | USP1 (0.41) | USP1WDR48PTGS2 | |
| SCHEMBL25254428 | 0.88 | USP1 (0.44) | USP1WDR48HDAC1HDAC6HDAC5 | |
| SCHEMBL22143253 | 0.88 | USP1 (0.44) | USP1WDR48HDAC1HDAC6HDAC5 | |
| SCHEMBL31293697 | 0.88 | USP1 (0.44) | USP1WDR48HDAC1HDAC6HDAC5 | |
| SCHEMBL31511354 | 0.85 | USP1 (0.43) | USP1WDR48PTGS2 | |
| SCHEMBL31254567 | 0.84 | USP1 (0.38) | USP1WDR48P2RX7PTGS2 | |
| SCHEMBL22143054 | 0.84 | USP1 (0.43) | USP1HDAC1HDAC6HDAC5HDAC8 | |
| SCHEMBL30320395 | 0.84 | USP1 (0.43) | USP1HDAC1HDAC6HDAC5HDAC8 | |
| SCHEMBL22143497 | 0.82 | USP1 (0.44) | USP1HDAC1HDAC6HDAC5HDAC8 | |
| SCHEMBL31138673 | 0.82 | USP1 (0.44) | USP1HDAC1HDAC6HDAC5HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024233665-A1 | COMPOUNDS AND THEIR USE AGAINST CANCER | TANGO THERAPEUTICS, INC. (US) | 2024-11-14 | — | — | WO | disclosed |
| US-20230219965-A1 | NITROGEN-CONTAINING FUSED BICYCLIC COMPOUNDS AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS | KSQ Therapeutics, Inc. | 2023-07-13 | — | — | US | disclosed |
| US-20230219965-A1 | NITROGEN-CONTAINING FUSED BICYCLIC COMPOUNDS AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS | KSQ Therapeutics, Inc. | 2023-07-13 | — | — | US | disclosed |
| EP-4161494-A1 | NITROGEN-CONTAINING FUSED BICYCLIC COMPOUNDS AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS | KSQ Therapeutics, Inc. (US) | 2023-04-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219965-A1 | NITROGEN-CONTAINING FUSED BICYCLIC COMPOUNDS AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS | USP1, USP8, USP7 | USP1 1/4885WDR48 930/4885HDAC1 291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.